Federated Hermes
IOVA icon

Federated Hermes’s Iovance Biotherapeutics IOVA Stock Holding History

Federated Hermes’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73K Sell
656
-11,566
-95% -$43.9K ﹤0.01% 1973
2026
Q1 		$42.9K Buy
12,222
+2,671
+28% +$8.54K ﹤0.01% 1693
2025
Q4 		$26.1K Sell
9,551
-5,560
-37% -$12.9K ﹤0.01% 1724
2025
Q3 		$32.8K Buy
15,111
+6,095
+68% +$14.4K ﹤0.01% 1741
2025
Q2 		$15.5K Buy
+9,016
New +$22.4K ﹤0.01% 1750
2023
Q1 		– Sell
-10,669
Closed -$68.2K – 2187
2022
Q4 		$68.2K Buy
+10,669
New +$83.3K ﹤0.01% 1682
2022
Q2 		– Sell
-15,768
Closed -$263K – 2222
2022
Q1 		$263K Buy
+15,768
New +$244K ﹤0.01% 1555
2021
Q2 		– Sell
-27,017
Closed -$855K – 2268
2021
Q1 		$855K Sell
27,017
-3,948
-13% -$164K ﹤0.01% 1431
2020
Q4 		$1.44M Buy
30,965
+14,597
+89% +$580K ﹤0.01% 1187
2020
Q3 		$539K Sell
16,368
-29
-0.2% -$889 ﹤0.01% 1459
2020
Q2 		$450K Buy
+16,397
New +$539K ﹤0.01% 1498
2020
Q1 		– Sell
-150
Closed -$4K – 2294
2019
Q4 		$4K Sell
150
-44,277
-100% -$1.01M ﹤0.01% 1979
2019
Q3 		$809K Sell
44,427
-298,456
-87% -$6.6M ﹤0.01% 1350
2019
Q2 		$8.41M Buy
342,883
+342,421
+74,117% +$5.16M 0.02% 638
2019
Q1 		$4K Sell
462
-43
-9% -$418 ﹤0.01% 1999
2018
Q4 		$4K Sell
505
-31,495
-98% -$304K ﹤0.01% 2010
2018
Q3 		$360K Sell
32,000
-57,911
-64% -$822K ﹤0.01% 1526
2018
Q2 		$1.15M Buy
89,911
+23,659
+36% +$346K ﹤0.01% 1239
2018
Q1 		$1.12M Buy
66,252
+65,789
+14,209% +$996K ﹤0.01% 1196
2017
Q4 		$4K Buy
+463
New +$3.72K ﹤0.01% 2015
2016
Q4 		– Sell
-1,221
Closed -$10K – 2142
2016
Q3 		$10K Buy
+1,221
New +$10.3K ﹤0.01% 1819
2015
Q4 		– Sell
-60,000
Closed -$346K – 2115
2015
Q3 		$346K Hold
60,000
– – ﹤0.01% 1381
2015
Q2 		$550K Buy
+60,000
New +$670K ﹤0.01% 1307

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Federated Hermes's IOVA Position: Q2 2026 in Review

Federated Hermes reduced its Iovance Biotherapeutics (IOVA) stake by 95% in Q2 2026, selling an estimated $43.9K and leaving 656 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1973.

Federated Hermes first reported a position in IOVA in Q2 2015 and has held it in 23 quarters since. The position peaked at $8.41M in Q2 2019. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Federated Hermes held 656 shares of Iovance Biotherapeutics worth $2.73K as of Q2 2026.
  • Federated Hermes sold 11,566 Iovance Biotherapeutics shares in Q2 2026, an estimated $43.9K.
  • Iovance Biotherapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1973 holding.
  • Federated Hermes first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 23 quarters since.
  • Federated Hermes's Iovance Biotherapeutics position peaked at $8.41M in Q2 2019.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.